Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | ABL2 | P42684 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 5/20 | 0.40 |
| ▸ | TTR | P02766 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 4/20 | 0.37 |
| ▸ | KIF5B | P33176 | 2/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444815 | 0.86 | NR1H2 (0.39) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL426723 | 0.86 | HTT (0.54) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL1655800 | 0.82 | ACHE (0.48) | EGFRRBP4TTRHRH3MET | |
| SCHEMBL18374088 | 0.78 | SYK (0.47) | HTTL3MBTL1RBP4TTR | |
| SCHEMBL427897 | 0.78 | NOS3 (0.39) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL13419330 | 0.78 | EGFR (0.53) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3814357 | 0.78 | EGFR (0.53) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL13861972 | 0.78 | POLB (0.48) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL6230486 | 0.78 | ACHE (0.44) | RBP4TTRMAOAMAOBHRH3 | |
| SCHEMBL2031770 | 0.75 | EGFR (0.44) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | EGFR 572/4885KDR 8/4885FGFR1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.